EBioMedicine (Sep 2022)

Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine

  • David W. Hawman,
  • Kimberly Meade-White,
  • Chad Clancy,
  • Jacob Archer,
  • Troy Hinkley,
  • Shanna S. Leventhal,
  • Deepashri Rao,
  • Allie Stamper,
  • Matthew Lewis,
  • Rebecca Rosenke,
  • Kyle Krieger,
  • Samantha Randall,
  • Amit P. Khandhar,
  • Linhue Hao,
  • Tien-Ying Hsiang,
  • Alexander L. Greninger,
  • Michael Gale, Jr,
  • Peter Berglund,
  • Deborah Heydenburg Fuller,
  • Kyle Rosenke,
  • Heinz Feldmann,
  • Jesse H. Erasmus

Journal volume & issue
Vol. 83
p. 104196

Abstract

Read online

Summary: Background: In late 2021, the SARS-CoV-2 Omicron (B.1.1.529) variant of concern (VoC) was reported with many mutations in the viral spike protein that were predicted to enhance transmissibility and allow viral escape of neutralizing antibodies. Within weeks of the first report of B.1.1.529, this VoC has rapidly spread throughout the world, replacing previously circulating strains of SARS-CoV-2 and leading to a resurgence in COVID-19 cases even in populations with high levels of vaccine- and infection-induced immunity. Studies have shown that B.1.1.529 is less sensitive to protective antibody conferred by previous infections and vaccines developed against earlier lineages of SARS-CoV-2. The ability of B.1.1.529 to spread even among vaccinated populations has led to a global public health demand for updated vaccines that can confer protection against B.1.1.529. Methods: We rapidly developed a replicating RNA vaccine expressing the B.1.1.529 spike and evaluated immunogenicity in mice and hamsters. We also challenged hamsters with B.1.1.529 and evaluated whether vaccination could protect against viral shedding and replication within respiratory tissue. Findings: We found that mice previously immunized with A.1-specific vaccines failed to elevate neutralizing antibody titers against B.1.1.529 following B.1.1.529-targeted boosting, suggesting pre-existing immunity may impact the efficacy of B.1.1.529-targeted boosters. Furthermore, we found that our B.1.1.529-targeted vaccine provides superior protection compared to the ancestral A.1-targeted vaccine in hamsters challenged with the B.1.1.529 VoC after a single dose of each vaccine. Interpretation: Our data suggest that B.1.1.529-targeted vaccines may provide superior protection against B.1.1.529 but pre-existing immunity and timing of boosting may need to be considered for optimum protection. Funding: This research was supported in part by the Intramural Research Program, NIAID/NIH, Washington Research Foundation and by grants 27220140006C (JHE), AI100625, AI151698, and AI145296 (MG).

Keywords